Skip to content
PatientMatchFind trials
Study details
Enrolling now

A Clinical Trial of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Merck Sharp & Dohme LLC
NCT IDNCT07190248ClinicalTrials.gov data as of Apr 2026
Check if I qualifyBack to resultsClinicalTrials.gov
Phase

Phase 3

Target enrollment

675

Study length

about 6.8 years

Ages

18+

Locations

7 sites in AL, CT, FL +4

About this study

This trial is testing if it medicines MK-1084 and subcutaneous pembrolizumab can be used to treat non-small cell lung cancer when given together. The goal is to learn if people who receive MK-1084 with subcutaneous pembrolizumab live longer without the cancer growing or spreading than in people who receive subcutaneous pembrolizumab with chemotherapy.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Receive Pembrolizumab (+) Berahyaluronidase alfa
  • 2.Take Carboplatin
  • 3.Take Cisplatin
  • +2 more
PhasePhase 3
DrugCarboplatin
Primary goalProgression Free Survival (PFS) in Participants with Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low9%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

carboplatin, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), pemetrexed

Drug routes

injection, intravenous, infusion, injection (Injection)

Endpoints

Primary: Progression Free Survival (PFS) in Participants with Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%

Secondary: Change from Baseline in Chest Pain Score (Item 40) on the EORTC QLQ-LC13, Change from Baseline in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire (EORTC QLQ-LC13), Change from Baseline in Dyspnea Score (Item 8) on the EORTC QLQ-C30, Change from Baseline in Global Health Status/Quality of Life (GHS/QoL) (Items 29, 30) on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30), Duration of Response (DOR), Number of Participants Who Discontinued Study Treatment Due to an AE, Number of Participants Who Experienced One or More Adverse Events (AEs), ORR in Participants with PD-L1 TPS ≥1%

Body systems

Oncology

Check if I qualifyView on ClinicalTrials.gov